Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Tekijä Barr, Paul M., Saylors, Gene B., Spurgeon, Stephen E., Cheson, Bruce D., Greenwald, Daniel R., O’Brien, Susan M., Liem, Andre K. D., Mclntyre, Rosemary E., Joshi, Adarsh, Abella-Dominicis, Esteban, Hawkins, Michael J., Reddy, Anita, Di Paolo, Julie, Lee, Hank, He, Joyce, Hu, Jing, Dreiling, Lyndah K., Friedberg, Jonathan W.
Julkaisussa Blood (2016)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro...

Tekijä Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter
Julkaisussa Lancet Oncol (2017)

Risk Model for Overall Survival in Relapsed or Refractory Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies

Tekijä Soumerai, Jacob D., Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E., Shanafelt, Tait D., Rabe, Kari G., Byrd, John C., Chanan-Khan, Asher A., Furman, Richard R., Hillmen, Peter, Jones, Jeffrey, Seymour, John F., Sharman, Jeffrey P., Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K., Bhargava, Pankaj, Howes, Angela, James, Danelle F., Zelenetz, Andrew D.
Julkaisussa Lancet Haematol (2019)